NTU Hospital links metabolism to mortality

Liver disease remains a major health issue in Taiwan, driven by the high prevalence of chronic hepatitis B (HBV) and hepatitis C (HCV). A research team at National Taiwan University (NTU) Hospital, led by Vice Superintendent Jia-Horng Kao, has been investigating the interaction between hepatitis viruses and metabolic abnormalities. Their latest findings, published in the Journal of Hepatology, have drawn global attention.

Prof. Tung-Hung Su and Dr. Shang-Chin Huang reported that HBV patients with metabolic syndrome face a significantly higher risk of death. In contrast, those with only simple fatty liver but no other metabolic issues have a 50% lower long-term mortality rate. For HCV, Prof. Chen-Hua Liu showed that even after patients are cured with direct-acting antiviral (DAA) therapy, those with metabolic-associated fatty liver disease (e.g., diabetes, hypertension, obesity) remain at a substantially higher risk of developing hepatocellular carcinoma (HCC). These findings stress the importance of early intervention for metabolic abnormalities alongside antiviral treatment.

Prof. Jun-Ren Liu, Director of National Taiwan University (NTU) Hospital’s Hepatitis Research Center, emphasized that in addition to controlling hepatitis viruses, patients must also manage metabolic health through weight control, diet, and regular monitoring. Timely screening for blood pressure, blood sugar, and lipid abnormalities, combined with regular liver ultrasound, can help reduce risks of cirrhosis and liver cancer and improve long-term prognosis.

Full articles:

https://www.journal-of-hepatology.eu/article/S0168-8278(24)02763-6/fulltext

https://www.journal-of-hepatology.eu/article/S0168-8278(24)02578-9/fulltext